Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds

Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug. The post Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds appeared first on…

Read More

Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes

By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders. The post Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes appeared first on MedCity News.

Read More

Welcome to the (U.S. Science) Apocalypse

By KIM BELLARD I’m starting to feel like I’m beating a dead horse, having already written a couple times recently about the Trump Administration’s attacks on science, but the hits just keep on coming. Last Friday, for example, not only did the Administration’s proposed 2026 budget slash National Science Foundation (NSF) funding by over 50%,…

Read More